TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04146766

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eHealth
Description: The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eHealth
Description: The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
Study: NCT04701541

Intervention type: DEVICE
Group type: OTHER
Intervention: Diaphragmatic Ultrasound
Description: Diaphragmatic ultrasound is non-invasive, portable, quick to perform, with a linear relationship between diaphragmatic movement and inspired volume. In eligible patients, a preoperative baseline ultrasound evaluation of the diaphragm and lungs is accomplished. Evaluation will be performed by a single operator, blinded to the arterial blood gas analysis values. In a semi recumbent position, patients will be asked to rest and breath quietly. An anterior approach will be carried out applying freehand transducer on abdomen at the right midclavicular line immediately below the costal margin with firm pressure, steering in cranial direction. A B-mode transverse scanning will be performed looking across the liver with gallbladder in the middle. Measurements will be recorded by the M-mode frozen images. The M-mode modality will be used to study DIA. The best sinusoidal curve will be considered for measurements.
Study: NCT02074605

Intervention type: BIOLOGICAL
Intervention: Interferon alpha
Study: NCT01220362

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacain 0.125%
Description: Bupivacain 0.125%

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacain 0.125%/Fentanyl 2mcg/ml
Description: Bupivacain 0.125%/Fentanyl 2mcg/ml
Study: NCT02011295

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ankle arthroscopy with debridement and microfracture of the OLT
Description: ankle arthroscopy with debridement and microfracture of the OLT

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ankle arthroscopy with debridement and microfracture of the OLT
Description: ankle arthroscopy with debridement and microfracture of the OLT

Intervention type: OTHER
Group type: OTHER
Intervention: Bone Marrow Aspirate injection
Study: NCT00008450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT01371032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VideoMiller
Description: Video-Miller laryngoscope, using the screen (Video laryngoscopy group)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
Study: NCT02248558

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Video
Description: Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourced Video
Description: Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
Study: NCT04198532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast bath
Description: Contrast bath (hot and cold therapy)
Study: NCT00998244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet - very low carb or low fat
Description: Diet comparison in Gastroesophageal Reflux Disease

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet - very low carb or low fat
Description: Diet comparison in Gastroesophageal Reflux Disease
Study: NCT04234724

Intervention type: OTHER
Group type: OTHER
Intervention: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Description: Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Description: Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Study: NCT04158193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks.
Study: NCT04198532

Intervention type: OTHER
Group type: OTHER
Intervention: Contrast bath
Description: Contrast bath (hot and cold therapy)
Study: NCT03989830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second-line chemotherapy
Description: choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: 7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
Study: NCT03823664

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory Fitness
Description: Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory Fitness
Description: Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory Fitness
Description: Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
Study: NCT04111562

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cranioplasty
Description: Bone grafts
Study: NCT03056443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
Study: NCT00190775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
Study: NCT02604537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone
Description: 1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
Study: NCT04892056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Friction Mechanics
Description: anterior segment retraction using elastomeric power chains
Study: NCT00190775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
Study: NCT04820270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous T regulatory cells
Description: Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
Study: NCT01443013

Intervention type: OTHER
Intervention: Renal Transplant
Description: urinary sample at month 3, 6 and 12
Study: NCT02859038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upfront cytoreductive surgery
Description: Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interval debulking surgery
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
Study: NCT02160418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial and Cognitive Incentives
Study: NCT02290210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: URC102 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102 0.5mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: URC102 1.0mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: URC102 2.0mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01148173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined systemic and intrathecal chemotherapy followed by HD-ASCT
Description: Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
Study: NCT04768582

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay
Description: The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
Study: NCT03993015

Intervention type: OTHER
Intervention: Help to diagnosis software
Description: Help to diagnosis software
Study: NCT01675622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine tablets 10mg and 20mg, oral every 4-6 hours
Study: NCT00950989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brodalumab
Description: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: at least 5 mg per week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: at least 5 mg per week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: at least 5 mg per week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: at least 5 mg per week
Study: NCT01684657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
Study: NCT01039961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod 1 mg
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod
Description: IV infusion (dose to be determined based on PK from first dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losmapimod 15 mg
Description: oral, two 7.5 mg tablets
Study: NCT00783367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study
Study: NCT00308724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: 8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone check-in
Description: Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
Study: NCT00783367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
Study: NCT02664961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
Study: NCT01207466

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A investigational contact lens
Description: Investigational, soft contact lens for astigmatism worn on a daily disposable basis.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A investigational contact lens
Description: Investigational, soft contact lens for astigmatism worn on a daily disposable basis.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A commercial contact lens
Description: Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A commercial contact lens
Description: Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
Study: NCT02664961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be dosed every two weeks.
Study: NCT02310373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine free hookah smoking
Description: Subjects will smoke waterpipe in a controlled research environment
Study: NCT00095563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study: NCT02444715

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPSYS
Description: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
Study: NCT02067624

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thai massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage
Study: NCT00095563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01661322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin, Dipyradimole, Clopidogrel
Description: Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
Study: NCT03501979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib study drug is given in tablet form and taken daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is approved by the FDA and is available commercially as an oral drug.
Study: NCT01517035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
Study: NCT05163704

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
Study: NCT01696357

Intervention type: DEVICE
Intervention: Automated Device for Asthma Monitoring (ADAM)
Description: Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
Study: NCT04518059

Intervention type: PROCEDURE
Intervention: punch skin biopsy
Description: An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.

Intervention type: PROCEDURE
Intervention: punch skin biopsy
Description: An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
Study: NCT01804803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.
Description: Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of regular glucometer
Study: NCT00938951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® Ultra
Description: Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%